Ameriprise’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-207,787
| Closed | -$2.07M | – | 4123 |
|
|
2025
Q2 | $2.07M | Buy |
207,787
+9,885
| +5% | +$79.6K | ﹤0.01% | 2936 |
|
|
2025
Q1 | $1.18M | Sell |
197,902
-7,286
| -4% | -$53.5K | ﹤0.01% | 3141 |
|
|
2024
Q4 | $1.58M | Buy |
205,188
+143,672
| +234% | +$1.23M | ﹤0.01% | 3051 |
|
|
2024
Q3 | $628K | Sell |
61,516
-17,953
| -23% | -$274K | ﹤0.01% | 3408 |
|
|
2024
Q2 | $1.18M | Buy |
79,469
+685
| +0.9% | +$9.81K | ﹤0.01% | 3092 |
|
|
2024
Q1 | $1.07M | Buy |
78,784
+6,064
| +8% | +$66.1K | ﹤0.01% | 3132 |
|
|
2023
Q4 | $796K | Sell |
72,720
-60,499
| -45% | -$600K | ﹤0.01% | 3284 |
|
|
2023
Q3 | $1.46M | Sell |
133,219
-215
| -0.2% | -$2.75K | ﹤0.01% | 2976 |
|
|
2023
Q2 | $1.77M | Sell |
133,434
-5,206
| -4% | -$74.2K | ﹤0.01% | 2935 |
|
|
2023
Q1 | $1.89M | Buy |
138,640
+16,653
| +14% | +$298K | ﹤0.01% | 2875 |
|
|
2022
Q4 | $2.38M | Sell |
121,987
-176,346
| -59% | -$3.45M | ﹤0.01% | 2725 |
|
|
2022
Q3 | $5.68M | Buy |
298,333
+203,749
| +215% | +$4.69M | ﹤0.01% | 2119 |
|
|
2022
Q2 | $1.95M | Buy |
94,584
+5,285
| +6% | +$125K | ﹤0.01% | 2820 |
|
|
2022
Q1 | $2.87M | Buy |
+89,299
| New | +$3.24M | ﹤0.01% | 2750 |
|
Other funds holding ITOS
Ameriprise's ITOS Position: Q3 2025 in Review
Ameriprise sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 207,787 shares — an estimated $2.07M sold.
Ameriprise first reported a position in ITOS in Q1 2022 and held it in 14 quarters. The position peaked at $5.68M in Q3 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Ameriprise reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Ameriprise sold 207,787 iTeos Therapeutics shares in Q3 2025, an estimated $2.07M.
- Ameriprise first reported a position in iTeos Therapeutics in Q1 2022 and held it in 14 quarters.
- Ameriprise's iTeos Therapeutics position peaked at $5.68M in Q3 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Ameriprise's 13F filing for Q3 2025, filed 14 Nov 2025.